Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Karlo Huenerbein"'
Autor:
Parvis Sadjadian, Vera Kolatzki, Tatjana Becker, Kai Wille, Martin Griesshammer, Hannah Marchi, Christiane Fuchs, Karlo Huenerbein, Ellen Jagenberg, Raphael Meixner
Publikováno v:
Eur. J. Haematol., DOI: 10.1111/ejh.13721 (2021)
In patients with bcr-abl-negative myeloproliferative neoplasms (MPN), concerns are often raised about the use of anticoagulants because of an increased bleeding risk. However, there are few MPN studies focusing on bleeding. To investigate bleeding co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42d7fae50f7a5f7c8040a10a1065e883
https://doi.org/10.1111/ejh.13721
https://doi.org/10.1111/ejh.13721
Autor:
Tatjana Becker, Johannes Bernhardt, Karlo Huenerbein, Kai Wille, Martin Griesshammer, Parvis Sadjadian, Vera Kolatzki
Publikováno v:
European journal of haematologyREFERENCES. 107(1)
OBJECTIVES Pregnancies in women with polycythemia vera (PV) are associated with an increased risk of PV-related maternal complications and often result in miscarriage. Recommendations for the management of PV pregnancies are mainly based on studies w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffd9b8688db1a5a2c908269909dd8743
https://pubmed.ncbi.nlm.nih.gov/33763907
https://pubmed.ncbi.nlm.nih.gov/33763907
Autor:
Rudolf Wallmann, Hannah Marchi, Tatjana Becker, Rohit Sekhri, Raphael Meixner, Vera Kolatzki, Karlo Huenerbein, Kai Wille, Martin Griesshammer, Parvis Sadjadian, Christiane Fuchs
Publikováno v:
Ann. Hematol., DOI: 10.1007/s00277-021-04647-0 (2021)
Annals of Hematology
Annals of Hematology
Recently, there has been increased concern about a risk of secondary malignancies (SM) occurring in myelofibrosis (MF) patients receiving ruxolitinib (RUX). In polycythemia vera (PV), on the other hand, only limited data on the risk of SM under RUX t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78e9b891f2bf7f1e4a71891e4bf68512
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=62859
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=62859
Autor:
Eva Deventer, Carina Engelhardt, Karlo Huenerbein, Tatjana Becker, Martin Griesshammer, Kai Wille, Parvis Sadjadian, Vera Kolatzki
Publikováno v:
Annals of Hematology
In patients with BCR-ABL-negative myeloproliferative neoplasms (MPN), arterial or venous thromboembolic events (ATE/VTE) are a major burden. In order to control these complications, vitamin K antagonists (VKA) are widely used. There is no robust evid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8c615733697e75cee7505845eab765d
https://hss-opus.ub.ruhr-uni-bochum.de/opus4/files/9570/HuenerbeinKarlo20112020.pdf
https://hss-opus.ub.ruhr-uni-bochum.de/opus4/files/9570/HuenerbeinKarlo20112020.pdf